All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy

1mon ago, source: Hosted on MSN

Earnings Estimate Revisions for Caribou Biosciences, Inc. For the fiscal year ending December 2024, this company is expected to earn -$1.69 per share, which is a change of -22.5% from the year-ago ...

With 65% institutional ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst the big guns

17d ago, source: Yahoo Finance

Caribou Biosciences already has institutions on the ... Looking at our data, we can see that the largest shareholder is BlackRock, Inc. with 7.8% of shares outstanding. PFM Health Sciences ...

Caribou Biosciences Stock (NASDAQ:CRBU), Analyst Ratings, Price Targets, Predictions

1mon ago, source: Benzinga.com

There is no last downgrade for Caribou Biosciences.

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

on MSN ago, source:

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. Shares of Kura ...

Caribou Biosciences Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: WOOD-TV

March 11, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the ...

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

14d ago, source: Business Insider

April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of ...

Caribou Biosciences Inc (CRBU)

2d ago, source: Investing

After-Hours Stock Movers: ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) 20% HIGHER; announced that it has expanded its current licensing agreement for trofinetide with Neuren ...

Caribou Biosciences Inc Ordinary Shares

24d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Stockhouse

March 11, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth ...

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

14d ago, source: Stockhouse

April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its ...